1 Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Roma.
2 Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma.
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
myeloid leukemia (AML) in patients over the age of 60 carries a poor
prognosis, mainly due to unsatisfactory control of leukemia with
Old Patients with AML
Prognosis and Initial Treatment
Allogeneic Hemopoietic Stem Cell Transplantation (HSCT)
Conditioning Regimens in Older AML
Comparing Myeloablative Regimens with NMA or RIC
Graft versus Host Disease
Transplant Related Mortality
Is Allogeneic HSCT the Best Post-Remission Therapy for Older Patients with AML?
Older AML Patients Beyond the First Remission
Exceeding the Limit of 70 Years of Age
The Role of Cytogenetics
Targeted Therapy and HSCT
Geriatric Assessment in older AML
1. Older patients with AML are assessed for biologic and geriatric
classification; HLA typing and induction is carried out for CGA FIT
patients; as soon as a suitable donor is identified , patients should
proceed to HSCT:AML=acute myeloid leukemia; Low risk AML=according to
ELN2017 guidelines; intermediate high risk AML; CGA comprehensive
geriatric assessment; FIT, UNFIT, FRAIL=three categories of CGA; HLA
human leukocyte antigen; HSCT=Hemopoietic stem cell transplant;
suitable donor=HLA identical sibling; HLA identical unrelated donor;
family haploidentical donor; partially mismatched unrelated donor, cord